Ülke: Singapur
Dil: İngilizce
Kaynak: HSA (Health Sciences Authority)
Mycophenolate Mofetil
GOLDPLUS UNIVERSAL PTE LTD
L04AA06
TABLET, FILM COATED
Mycophenolate Mofetil 500 mg
ORAL
Prescription Only
CONCORD BIOTECH LIMITED
ACTIVE
2020-09-18
MOFECON TM VIMOF01-var (SIN) DESCRIPTION MOFECON TM 250: White to off white granular powder filled in size ‘1’ hard gelatin capsule with opaque blue cap imprinted ‘C3 250’ and opaque brown body. MOFECON TM 500: Lavender-colored, caplet-shaped, film-coated tablet, debossed with “C4” on one side and plain on the other side. COMPOSITION MOFECON TM 250: each capsule contains mycophenolate mofetil 250 mg. _Excipients:_ Microcrystalline cellulose, hydroxypropyl cellulose, povidone, croscarmellose sodium, talc, magnesium stearate. MOFECON TM 500: Each tablet contains mycophenolate mofetil 500 mg. _Excipients:_ Microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, indigo carmine aluminium lake, black iron oxide. Capsule shell (FD & C Blue 2, titanium dioxide, iron oxide red, iron oxide yellow, gelatin, water, SLS (sodium lauryl sulphate)). PHARMACODYNAMICS Mycophenolate mofetil is an immunosuppressive agents. Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the _de _ _novo_ pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on _ de novo_ synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells. PHARMACOKINETICS The pharmacokinetics of MMF have been studied in renal, cardiac and hepatic transplant patients. In general, the pharmacokinetic profile of MPA is similar in renal and in cardiac transplant patients. In the early transplant period, hepatic transplant patients receiving a 1.5g oral MMF dose or 1g i.v. MMF dose have similar MPA levels compared to renal transplant patients receiving 1g oral or i.v. MMF. ABSORPTION Following oral and intravenous administration, mycophenolate mofetil Belgenin tamamını okuyun